Introducing LUCENTIS Prefilled Syringe 0.5 mg

The efficacy and safety of LUCENTIS studied in 6 pivotal trials,† now in a 0.5 mg prefilled syringe

The following randomized, double-masked pivotal trials were conducted for the 4 LUCENTIS indications: wAMD: MARINA–Phase III, multicenter, 2-year, sham injection-controlled study; primary end point at 1 year. ANCHOR–Phase III, multicenter, 2-year, active treatment-controlled study; primary end point at 1 year. PIER–Phase IIIb, 2-year, sham injection-controlled study; primary end point at 1 year. HARBOR–Phase III, multicenter, 2-year, active treatment-controlled dose-response study; primary end point at 1 year. RVO: BRAVO–Phase III, multicenter, 1-year, sham injection-controlled study; primary end point at 6 months. CRUISE–Phase III, multicenter, 1-year, sham injection-controlled study; primary end point at 6 months. 1-7

See how LUCENTIS Prefilled Syringe 0.5 mg works

See the LUCENTIS full Prescribing Information containing the Instructions for Use.

Order LUCENTIS Prefilled Syringe 0.5 mg before your patient’s next scheduled appointment

LUCENTIS Prefilled Syringe 0.5 mg is available through LUCENTIS Direct and authorized specialty distributors.